Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Esthesioneuroblastoma, Olfactory

NCT01016639 2011-10-17

CORGI

Phase 1/2 Completed

106 enrolled

Gastrointestinal

Gallbladder Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Clinical Trials

T-DXd_HER2Low

TALENT

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

IPXELOX

Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer

Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP

Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP

Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

A Trial of RAD001/Capecitabine in Refractory Gastric Cancer

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer

Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

CORGI